References
Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19:2666
Boon T, Old LJ (1997) Cancer tumor antigens. Curr Opin Immunol 9:681
Cheville JC, Roche PC (1999) MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors. Mod Pathol 12:974
De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360
Flynn GC, Pohl J, Flocco MT, Rothman JE (1991) Peptide-binding specificity of the molecular chaperone BiP. Nature 353:726
Kawakami S, Yamashita F, Hashida M (2000) Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliv Rev 45:77
Ma JH, Sui YF, Ye J, Ya-Yu Huang, Zeng-Shan Li, Guang-Sheng Chen, Ping Qu, Hong-Ping Song, Xiu-Min Zhang (2005) Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54:907
Manmohan Singh, Derek O’Hagan (1999) Advances in vaccine adjuvants. Nat Biotechnol 17:1075
Melief CJ, Kast WM (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167
Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target specific nanoparticles: theory to practice. Pharmacol Rev 53:283
Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young KS, Chang J, Hamouda T, Olszewski MA, Baker JR Jr (2003) Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemlsion. Vaccine 21:3801
Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9:1647
Pan G, Shawer M, Oie S, Lu DR (2003) In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system. Pharm Res 20:738
Serguei V, Vinogradov, Tatiana K, Bronich, Alexander V Kabanov (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties, and interactions with cells. Adv Drug Deliv Rev 54:135
Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723
Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. J Orthop Res 15:128
Sun YJ, Wu DC, Cao YX, Sui YF (2005) Preparation and characterization of nanoemulsion. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21:69
Suzue K, Young RA (1996) Adjuvant-free Mycobacterium tuberculosis hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 156:873
Suzue K, Zhou X, Eisen HN, Young RA (1997) Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94:13146
Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684
Wu H, Ramachandran C, Bielinska AU, Kingzett K, Sun R, Weiner ND, Rossler BJ (2001) Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int J Pharm 221:23
Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF (2004) Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53:825
Zhu X, Zhao X, Burkholder WF, Gragerov A, Ogata CM, Gottesman ME, Hendrickson WA (1996) Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272:1606
Acknowledgments
This work was supported by grants from the China National Natural Science Foundation (No. 30271464).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ge, W., Sui, YF., Wu, DC. et al. MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo. Cancer Immunol Immunother 55, 841–849 (2006). https://doi.org/10.1007/s00262-005-0073-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-005-0073-y